Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Armodafinil | Piracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 75-150 mg once daily (for educational context only — prescription medication in most jurisdictions) | 1200-4800 mg/day divided into 2-3 doses |
| Timing | Early morning. 150 mg armodafinil provides comparable late-day wakefulness to 200 mg modafinil. Food delays Tmax by ~2-4 hours but does not affect total absorption. Half-life approximately 15-16.5 hours. | With or without food; split doses morning and afternoon to maintain plasma levels |
| Cycle Duration | Same as modafinil; not typically cycled in clinical use. | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment |
| Evidence Level | strong_human | moderate_human |
The isolated R-enantiomer of racemic modafinil, sharing the same primary mechanism — selective inhibition of the dopamine transporter (DAT) — but with distinct pharmacokinetics. The R-enantiomer has a terminal half-life of ~15 hours vs. ~4-5 hours for the S-enantiomer, resulting in 33-40% higher plasma AUC compared to equimolar racemic modafinil. This translates to more sustained wakefulness-promoting activity throughout the day. Same downstream activation of orexinergic, histaminergic, and noradrenergic pathways as modafinil.
75-150 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning. 150 mg armodafinil provides comparable late-day wakefulness to 200 mg modafinil. Food delays Tmax by ~2-4 hours but does not affect total absorption. Half-life approximately 15-16.5 hours.
Same as modafinil; not typically cycled in clinical use.
Positive allosteric modulator of AMPA receptors, binding at a unique site along the dimer interface to reduce desensitization and deactivation. Inhibits N-type calcium channels at clinically relevant CNS concentrations. Enhances membrane fluidity of neuronal phospholipids and modulates neurotransmission across cholinergic and glutamatergic systems.
1200-4800 mg/day divided into 2-3 doses
With or without food; split doses morning and afternoon to maintain plasma levels
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →